Measles Clinical Trial
Official title:
An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age
Verified date | January 2018 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary study objectives are:
- To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human
Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age
at the time of Dose 1 is as immunogenic as in healthy children of 12 months of age at
the time of Dose 1.
- To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval
to healthy children of 9 months of age at the time of Dose 1 is as immunogenic as in
healthy children of 12 months of age at the time of Dose 1.
- To demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval
to healthy children of 11 months of age and 9 months of age at the time of Dose 1 is
well-tolerated compared to children of 12 months of age at the time of Dose 1.
The first primary hypothesis was that a 2-dose regimen of ProQuad® rHA, administered at a
3-month interval to children of 11 months of age, would be non-inferior in terms of antibody
response rates to measles, mumps, rubella, and varicella at Day 42 following Dose 2, to the
same regimen in children of 12 months of age at the time of Dose 1.
If the first primary hypothesis was demonstrated, the second primary hypothesis was that a
2-dose regimen of ProQuad® rHA, administered at a 3-month interval to children of 9 months of
age, would be non-inferior in terms of antibody response rates to measles, mumps, rubella,
and varicella at Day 42 following Dose 2, to the same regimen in children of 12 months of age
at the time of Dose 1.
The secondary study objectives are:
- To describe the antibody titres to measles, mumps, rubella and varicella at Day 42
following Dose 1 and Dose 2 of ProQuad® rHA administered to healthy children from 9
months of age.
- To evaluate the safety profile of Dose 1 and Dose 2 of ProQuad® rHA administered to
healthy children from 9 months of age.
Status | Completed |
Enrollment | 1620 |
Est. completion date | December 29, 2008 |
Est. primary completion date | December 29, 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 9 Months and older |
Eligibility |
Inclusion Criteria: 1. Healthy subject of either gender of 9 months of age 2. Negative clinical history of measles, mumps, rubella, varicella or zoster 3. Informed consent form signed by both parents or legal representative 4. Parent(s) or legal representative able to attend all the scheduled visits with the subject and to understand and comply with the study procedures 5. Both parent or legal representative are over 18 years of age 6. Subject is affiliated to a health social security system Exclusion Criteria: 1. Febrile illness in the previous 3 days 2. Prior vaccination with a measles, mumps, rubella and/or varicella vaccine either alone or in any combination 3. Exposure to measles, mumps, rubella, varicella and/or zoster in the previous 30 days 4. Tuberculin test done in the previous 2 days 5. Severe chronic disease 6. Known active tuberculosis 7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition 8. Hereditary problems of fructose intolerance 9. Prior known sensitivity or allergy to any component of the vaccine 10. Known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems 11. Humoral or cellular immunodeficiency, 12. Immunosuppressive therapy [including systemic corticosteroids (a), given daily or on alternate days at high doses (>=2 mg/kg/day prednisone equivalent or >=20 mg/day if the subject's weight was >10 kg) during at least 14 days in the previous 30 days] 13. Family history of congenital or hereditary immunodeficiency 14. Receipt of immunoglobulins or blood-derived products in the previous 150 days or scheduled to be administered through Visit 5 15. Receipt of an inactivated vaccine in the previous 14 days 16. Receipt of a live non-study vaccine in the previous 28 days 17. Any medical condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives 18. Current participation or scheduled participation in any other clinical study through Visit 5 |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2 | Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 2 (received ProQuad® Dose 1 at 11 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA). Response and baseline seronegativity criteria were as follows: measles antibody titre =255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre =10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre =10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre =5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL. | Day 132 (6 weeks after ProQuad® Dose 2) | |
Primary | Percentage of Participants in Arm 1 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2 | Immunogenicity response rates were compared in participants with baseline seronegativity from Arm 1 (received ProQuad® Dose 1 at 9 months) and Arm 3 (received ProQuad® Dose 1 at 12 months). Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre =255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre =10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre =10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre =5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL. | Day 132 (6 weeks after ProQuad® Dose 2) | |
Primary | Percentage of Participants With Solicited Injection-site Adverse Reactions | The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1. | Day 1 to Day 4 (up to 4 days after ProQuad® Dose 1) | |
Primary | Percentage of Participants Experiencing Unsolicited Injection-site Adverse Reactions | The percentage of participants with unsolicited injection-site reactions after ProQuad® Dose 1 was determined. | Up to Day 28 (up to 28 days after ProQuad® Dose 1) | |
Primary | Percentage of Participants Experiencing a Systemic Adverse Event After ProQuad® Dose 1 | The percentage of participants with systemic adverse events after ProQuad® Dose 1 was determined. | Up to Day 28 (up to 28 days after ProQuad® Dose 1) | |
Primary | Percentage of Participants With Rectal (or Rectal Equivalent) Temperature = 39.4°C | The percentage of participants with a rectal (or rectal equivalent) temperature = 39.4°C after ProQuad® Dose 1 was determined. | Up to Day 28 (up to 28 days after ProQuad® Dose 1) | |
Secondary | Geometric Mean Titres (GMT) to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 1 | Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the first ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre <255 mIU/mL; mumps antibody titre <10 ELISA Ab units mL; rubella antibody titre <10 IU/mL; and varicella antibody titre <1.25 gpELISA units/mL. | Day 42 (6 weeks after ProQuad® Dose 1) | |
Secondary | GMT to Measles, Mumps, Rubella, and Varicella After ProQuad® Dose 2 | Antibody titres (GMT) to measles, mumps, rubella, and varicella were determined after the second ProQuad® dose in participants with seronegative baseline values. Baseline seronegativity criteria were as follows: measles antibody titre <255 mIU/mL; mumps antibody titre <10 ELISA Ab units mL; rubella antibody titre <10 IU/mL; and varicella antibody titre <1.25 gpELISA units/mL. | Day 132 (6 weeks after ProQuad® Dose 2) | |
Secondary | Percentage of Participants With Varicella Antibody Titre = 1.25 gpELISA Units/mL | The percentage of participants with varicella antibody titre = 1.25 gpELISA units/mL 6 weeks after each ProQuad® dose was determined. | Day 132 (6 weeks after ProQuad® Dose 2) | |
Secondary | Percentage of Baseline Seronegative Participants Meeting Antibody Immunogenicity Response Criteria After ProQuad® Dose 1 | The percentage of baseline seronegative participants meeting measles, mumps, rubella, and varicella antibody response criteria after the first ProQuad® dose was determined. Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response and baseline seronegativity criteria were as follows: measles antibody titre =255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre =10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre =10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre =5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL. | Day 42 (6 weeks after ProQuad® Dose 1) | |
Secondary | Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 1 | The percentage of participants with rashes of interest after ProQuad® Dose 1 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash. | Up to Day 28 (up to 4 weeks after ProQuad® Dose 1) | |
Secondary | Percentage of Participants With Non-injection Site Rashes of Interest Following ProQuad® Dose 2 | The percentage of participants with rashes of interest after receiving ProQuad® Dose 2 was determined. Rashes of interest consisted of measles-like rash, rubella-like rash, varicella-like rash, zoster-like rash, and mumps-like rash. | Day 132 (6 weeks after ProQuad® Dose 2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04183114 -
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
|
Phase 2/Phase 3 | |
Completed |
NCT00092430 -
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
|
Phase 3 | |
Completed |
NCT02196285 -
Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
|
Phase 1 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00313950 -
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
|
Phase 4 | |
Completed |
NCT00402831 -
ProQuad® Intramuscular vs Subcutaneous
|
Phase 3 | |
Completed |
NCT00560755 -
Safety Study of ProQuad® rHA in Infants (V221-037)
|
Phase 3 | |
Completed |
NCT01878435 -
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
|
N/A | |
Completed |
NCT01777529 -
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
|
Phase 4 | |
Terminated |
NCT00258726 -
Immune Responses to Two Dose Varivax +/- MMR-II
|
Phase 1/Phase 2 | |
Completed |
NCT00109278 -
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
|
Phase 2 | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Completed |
NCT02880865 -
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
|
Phase 4 | |
Completed |
NCT01681992 -
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
|
Phase 3 | |
Completed |
NCT00751348 -
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
|
Phase 3 | |
Completed |
NCT01702428 -
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
|
Phase 3 | |
Completed |
NCT00969436 -
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
|
Phase 3 | |
Completed |
NCT00127010 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 | |
Completed |
NCT00388440 -
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
|
Phase 4 | |
Completed |
NCT03148990 -
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
|
Phase 2/Phase 3 |